During the past decade, London Regional Cancer Program conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 116 clinical trials were completed, i.e. on average, 93.5% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 47 clinical trials were completed. i.e. 123.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "London Regional Cancer Program" #1 sponsor was "NCIC Clinical Trials Group" with 64 trials, followed by "Radiation Therapy Oncology Group" with 59 trials sponsored, "Lawson Health Research Institute" with 41 trials sponsored, "National Cancer Institute (NCI)" with 40 trials sponsored and "Canadian Cancer Trials Group" with 40 trials sponsored. Other sponsors include 188 different institutions and companies that sponsored additional 70 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "London Regional Cancer Program" #1 collaborator was "National Cancer Institute (NCI)" with 137 trials as a collaborator, "NRG Oncology" with 33 trials as a collaborator, "NCIC Clinical Trials Group" with 27 trials as a collaborator, "SWOG Cancer Research Network" with 24 trials as a collaborator and "Eastern Cooperative Oncology Group" with 18 trials as a collaborator. Other collaborators include 287 different institutions and companies that were collaborators in the rest 154 trials.

According to Clinical.Site data, the most researched conditions in "London Regional Cancer Program" are "Prostate Cancer" (50 trials), "Breast Cancer" (42 trials), "Lung Cancer" (21 trials), "Head and Neck Cancer" (20 trials) and "Colorectal Cancer" (17 trials). Many other conditions were trialed in "London Regional Cancer Program" in a lesser frequency.

Most popular intervention types in "London Regional Cancer Program" are "Drug" (304 trials), "Radiation" (145 trials), "Other" (79 trials), "Procedure" (76 trials) and "Biological" (51 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (47 trials), "Laboratory Biomarker Analysis" (23 trials), "Placebo" (20 trials), "cisplatin" (20 trials) and "paclitaxel" (15 trials). Other intervention names were less common.

The vast majority of trials in "London Regional Cancer Program" are 288 trials for "All" genders, 86 trials for "Female" genders and 57 trials for "Male" genders.

Currently, there are 119 active trials in "London Regional Cancer Program". 2 are not yet recruiting, 36 are recruiting, 80 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 270 completed trials in London Regional Cancer Program, 1 suspended trials, and 28 terminated clinical trials to date.

Out of the total trials that were conducted in London Regional Cancer Program, 32 "Phase 1" clinical trials were conducted, 179 "Phase 2" clinical trials and 196 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 46 trials that are defined as “Not Applicable".